| Entries |
| Document | Title | Date |
|---|
| 20110207791 | COMPOSITION OF A 5-HT2A SEROTONIN RECEPTOR MODULATOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO - The present invention relates to certain compositions of a 5-HT | 08-25-2011 |
| 20120172407 | N-ALKOXYCARBOXAMIDES AND THEIR USE AS MICROBIOCIDES - Compounds of formula (I) in which the substituents are as defined in claim | 07-05-2012 |
| 20090192207 | Topical Formulations Comprising 1-N-Arylpyrazole Derivatives and Amitraz - The present invention provides for, inter alia, novel topical formulations comprising at least one 1-N-arypyrazole derivative and amitraz and to methods for treating, controlling, or preventing parasite infestations on mammals or birds The inventive formulations include spot-on, pour-on or spray formulations and may include a further ectoparasiticide, such as an IGR compound, an avermectin or milbemycin derivative, or a pyrethroid insecticides, and anthelmintics, such as benzimidazoles and imidazothiazoles. The inventive formulation provides a larger duration of parasite control at a faster rate of control. The inventive formula remains effective up to three months from the first application. Moreover, the inventive formulations prevent tick attachment to the animal, thereby providing protection against tick borne diseases. The ectoparasites which may be controlled, treated or prevented by the present invention includes ticks, fleas, mites, mange, lice, mosquitoes, flies and cattle grubs. | 07-30-2009 |
| 20110196009 | INHIBITORS OF Akt ACTIVITY - Invented are novel heterocyclic carboxamide compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis. | 08-11-2011 |
| 20100113551 | COMPOSITIONS COMPRISING (S)-2-AMINO-1-(4-CHLOROPHENYL)-1-[4-(1H-PYRAZOL-4-YL)-PHENYL]-ETHANOL AS MODULATOR OF PROTEIN KINASES - The invention provides a composition comprising (S) 2-amino-1-(4-chloro-phenyl)-1-[4-(1H-pyrazol-4-yl)-phenyl]-ethanol, wherein the composition is either substantially free of (R) 2-amino-1-(4-chloro-phenyl)-1-[4-(1H-pyrazol-4-yl)-phenyl]-ethanol or the composition contains a mixture of the (S) and (R) enantiomers in which the (S) enantiomer predominates. Also provided are processes for the preparation of the (S) 2-amino-1-(4-chloro-phenyl)-1-[4-(1H-pyrazol-4-yl)-phenyl]-ethanol, novel process intermediates and methods for making the novel process intermediates. | 05-06-2010 |
| 20100113553 | METHODS OF USING PROTEINACIOUS CHANNELS TO IDENTIFY PHARMACEUTICAL TREATMENTS AND RISKS, AND TREATMENTS RESULTING THEREFROM - Methods and therapeutic strategies utilizing proteinacious channels in lipid membranes of mammalian cells. The methods entail administering a pharmaceutical to a lipid membrane of a mammalian cell, and then determining the effect of the pharmaceutical on the electrophysiology of at least one vascular proteinacious channel of the lipid membrane, wherein the vascular proteinacious channel is a vascular Kv7 potassium channel and/or a vascular L-type calcium channel. The method can be used to identify pharmaceuticals that may be used to treat hypertension and/or vasospastic conditions, or to perform drug screening to assess potential cardiovascular risk of pharmaceuticals. | 05-06-2010 |
| 20100041726 | INHIBITORS OF Akt ACTIVITY - Invented are novel heterocyclic carboxamide compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis. | 02-18-2010 |
| 20090221660 | NOVEL CRYSTALLINE FORMS OF 4-[4-(2-ADAMANTYLCARBAMOYL)-5-TERT-BUTYL-PYRAZOL-1-YL]BENZOIC ACID 471 - New crystalline forms of 4-[4-(2-adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]benzoic acid; their use in the inhibition of 11βHSD1, processes for making them and pharmaceutical compositions comprising them are also described. | 09-03-2009 |
| 20120165383 | INFLAMMATORY EYE DISEASE - The present invention provides methods, kits and compositions for treating uveitis in a subject using Hsp90 inhibitors. | 06-28-2012 |
| 20120165382 | COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE - The present invention provides a compound, that is a 1-[(2-{[(alkyl or aryl)methyl]oxy}halo or haloalkyl substituted-phenyl)alkyl]-5-hydrocarbyl or substituted hydrocarbyl-1H-pyrazole carboxylic acid or alkylenylcarboxylic acid or a hydrocarbyl or substituted hydrocarbyl sulfonamide of said carboxylic acid or said alkylenylcarboxylic acid, provided however said compound is not a 3-carboxylic acid, a sulfonamide thereof, or a 3-methylenylcarboxylic acid. The compound may be represented by the following formula | 06-28-2012 |
| 20090306166 | Method of Controlling Phytopathogenic Diseases on Turfgrass - A method of controlling phytopathogenic diseases on turfgrass or on seeds thereof, which comprises applying to the turfgrass, the locus thereof or seeds thereof a composition, that, in addition to formulation adjuvants, comprises a fungicidally effective amount of at least one compound of formula I | 12-10-2009 |
| 20090111866 | Novel Compounds - The present invention provides compounds of formula (I): | 04-30-2009 |
| 20130072535 | PYRAZOLECARBOXAMIDE DERIVATIVES AND THEIR USE AS MICROBIOCIDES - Compounds of Formula (I) wherein R | 03-21-2013 |
| 20130072534 | COMPOSITIONS COMPRISING VENLAFAXINE AND CELECOXIB IN THE TREATMENT OF PAIN - The present invention relates to pharmaceutical compositions comprising venlafaxine and celecoxib and their uses as medicaments, more particularly for the treatment of pain, including chronic pain; or of depression in patients which suffer from pain or in patients with a chronic musculo-skeletal inflammatory illness, with the inflammatory illness preferably being selected from osteoarthritis or rheumatoid arthritis. | 03-21-2013 |
| 20120225921 | METHOD OF CONTROLLING PHYTOPATHOGENIC DISEASES ON TURFGRASS - A method of controlling phytopathogenic diseases on turfgrass or on seeds thereof, which comprises applying to the turfgrass, the locus thereof or seeds thereof a composition, that, in addition to formulation adjuvants, comprises a fungicidally effective amount of at least one compound of formula I | 09-06-2012 |
| 20090062364 | DEUTERIUM-ENRICHED CELECOXIB - The present application describes deuterium-enriched celecoxib, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 03-05-2009 |
| 20090036509 | N-(Ortho-Phenyl)-1-Methyl -3-Trifluoromethlpyrazole-4-Carboxanilides and Their Use as Fungicides - The present invention relates to N-(ortho-phenyl)-1-methyl-3-trifluoromethylpyrazole-4-carboxanilides of the formula I | 02-05-2009 |
| 20080293797 | Cycloalkane-Substituted Pyrazoline Derivatives, Their Preparation and Use as Medicaments - The present invention relates to Cycloalkane-substituted pyrazoline compounds of formula (I), methods for their preparation, medicaments comprising these compounds as well as their use for the preparation of a medicament for the treatment of humans and animals. | 11-27-2008 |
| 20110294863 | FUNGICIDE N-CYCLOALKYL-N-BICYCLIMETHYLENE-CARBOXAMIDE DERIVATIVES - The present invention relates N-cycloalkyl-N-bicyclicmethylene-carboxamide, thiocarboxamide or N-substituted carboximidamide derivatives of formula (I) wherein A represents a carbo-linked, 5-membered heterocyclyl group, T represents O or S, Z | 12-01-2011 |
| 20110021592 | ORGANIC NANOPARTICLES OBTAINED FROM MICROEMULSIONS BY SOLVENT EVAPORATION - The present invention provides a process for preparing a redispersible powder of nanoparticles of a water-insoluble organic compound, the process including the steps of: (i) preparing an oil-in-water microemulsion comprising a water-insoluble organic compound, a volatile water-immiscible organic solvent, water, and at least one surfactant; and (ii) removing the volatile water-immiscible organic solvent and the water so as to form the redispersible powder comprising said nanoparticles, wherein the nanoparticle are in a particulate form, and wherein the solubility of the water-insoluble organic compound is at least about 5 times greater than the solubility of the water-insoluble organic compound in unprocessed form. Step (i) can further include the addition of co-solvent or polymer. The water-insoluble organic compound can be a pharmaceutically active agent (in particular a statin), a cosmetic active agent, an anti oxidant, a preservative, a colorant, a food additive, an agriculturally active compound and a fragrance. | 01-27-2011 |
| 20110281925 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS - The invention is directed to compounds having the formula: | 11-17-2011 |
| 20110136885 | Synergistic Combination of Analgesic Compounds - The present invention relates to a pharmaceutical composition comprising as active substances:
| 06-09-2011 |
| 20110281924 | NOVEL MICROBIOCIDES - Compounds of formula (I), in which the substituents are as defined in claim | 11-17-2011 |
| 20110301215 | INHIBITORS OF PLASMA KALLIKREIN - The present invention provides compounds that inhibit the activity of plasma kallikrein (PK) and methods of preventing and treating the formation of thrombin during or after a PK dependent disease or condition, for example, after fibrinolysis treatment. | 12-08-2011 |
| 20110288142 | CRYSTALLINE N--5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride - An improved AKT inhibiting compound, crystalline N-{(1S)-2-amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride. | 11-24-2011 |
| 20090105325 | Substituted Pyrazolecarboxylic Acid Anilide Derivative or Salt Thereof, Intermediate Thereof, Agent for Agricultural and Horticultural Use, and Use Thereof - The substituted pyrazolecarboxanilide derivatives represented by of the formula (I) | 04-23-2009 |
| 20100035953 | Pyrazole Phenyl Derivatives - The invention relates to compounds of the formula I: | 02-11-2010 |
| 20100113552 | FUNGICIDAL COMPOSITION - A composition comprising (i) a compound of Formula (I), wherein R | 05-06-2010 |
| 20100267796 | THERAPEUTIC AGENT FOR IRRITABLE BOWEL SYNDROME - The present invention provides a therapeutic agent for irritable bowel syndrome which comprises, as an active ingredient, a compound having an adenosine uptake inhibitory activity, a therapeutic agent for irritable bowel syndrome which comprises, as an active ingredient, a tricyclic compound represented by formula (I) | 10-21-2010 |
| 20110124698 | Iodopyrazolyl Carboxanilides - This invention relates to novel intermediates used in the preparation of iodopyrazolylcarboxanilides of the formula (I) | 05-26-2011 |
| 20110086897 | (E)-N-(2-Amino-phenyl)-3--acrylamide salts - A salt of (E)-N-{2-amino-phenyl)-3-{1-[4-(1-methyl-1H-pyrazol-4-yl)-beπzenesulfonyl]-1H-pyrrol-3-yl)-acrylamide selected from the group consisting of the hydrobromide, methansulfonate, hemi ethane-1,2-disulfonate, benzenesulfonate, toiuenesulfonate and 2-naphthalenesulfonate. | 04-14-2011 |
| 20120035237 | PYRAZOLE AND TRIAZOLE CARBOXAMIDES AS CRAC CHANN EL INHIBITORS - The present invention relates to amide compounds, processes for their preparation, intermediates usable in these processes, pharmaceutical compositions containing these compounds and to their use in therapy. | 02-09-2012 |
| 20120035236 | Pyrazolyl Acrylonitrile Compounds and Uses Thereof - A kind of pyrazolyl acrylniitrile compounds represented by the structures of formula I or stereoisomers thereof are disclosed in the present invention. | 02-09-2012 |
| 20100087502 | Indazoles Used To Treat Estrogen Receptor Beta Mediated Disorders - The present invention relates to novel indazole derivatives having pharmacological activity, processes for their preparation, compositions containing them and uses of these compounds in the treatment of estrogen receptor beta mediated diseases. | 04-08-2010 |
| 20120108645 | NOVEL MICROBIOCIDES - Compounds of formula (I) in which the substituents are as defined in claim | 05-03-2012 |
| 20090143454 | Pyrazoline Derivatives and Their Use As Pesticides - The present invention relates to novel pyrazoline derivatives of the formula (I) | 06-04-2009 |
| 20090088463 | Pyrazoles Useful in the Treatment of Inflammation - There is provided compounds of formula (I), wherein X | 04-02-2009 |
| 20110207790 | PROCESSES USEFUL FOR THE PREPARATION OF 1-[3-(4-BROMO-2-METHYL-2H-PYRAZOL-3-YL)-4-METHOXY-PHENYL]-3-(2,4-DIFLUORO- -PHENYL)UREA AND CRYSTALLINE FORMS RELATED THERETO - The present invention is directed to processes and intermediates useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea (Compound I), crystalline forms and solvate forms thereof; and compositions comprising 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea, crystalline forms and solvate forms thereof prepared by processes as described herein. | 08-25-2011 |
| 20100280089 | USE OF INHIBITORS OF JUN N-TERMINAL KINASES FOR THE TREATMENT OF GLAUCOMATOUS RETINOPATHY AND OCULAR DISEASES - Compositions and methods for the treatment of glaucoma and other ocular diseases are disclosed. The compositions and methods are particularly directed to the use inhibitors of Jun N-terminal kinases (JNK), such as SP600125 in the treatment of glaucoma and other ocular diseases. | 11-04-2010 |
| 20090312386 | NOVEL CRYSTALS OF SUBSTITUTED PHENYLALKANOIC ACID AND METHOD OF PRODUCING THE SAME - [Object] In the case of using 3-[3-amino-4-(indan-2-yloxy)-5-(1-methyl-1H-indazol-5-yl)phenyl]propionic acid, methyl 3-[4-(indan-2-yloxy)-3-(1-methyl-1H-indazol-5-yl)-5-nitrophenyl]propionate, or methyl 3-[3-amino-4-(indan-2-yloxy)-5-(1-methyl-1H-indazol-5-yl)phenyl]propionate as a medicine, more preferable aspects or improved methods are provided. | 12-17-2009 |
| 20080269309 | PDK-1/AKT SIGNALING INHIBITORS - Use of a new class of phosphoinositide-dependent kinase-1 (PDK-1) inhibitors of formula I for inducing apoptosis in unwanted rapidly proliferating cells, for treating, inhibiting, or delaying the onset of cancer, and for preventing restenosis in a subject that has undergone an angioplasty or stent: | 10-30-2008 |
| 20100137394 | PYRAZOLE INHIBITORS OF WNT SIGNALING - The invention provides inhibitors of Wnt signaling that are useful as a therapeutic agents for treating malignancies where the compounds have the general formula I: wherein R1 to R7 and Z are as defined herein. | 06-03-2010 |
| 20110269808 | COMPOSITIONS COMPRISING (S)-2-AMINO-1-(4-CHLOROPHENYL)-1-[4-(1H-PYRAZOL-4-YL)-PHENYL]-ETHANOL AS MODULATOR OF PROTEIN KINASES - The invention provides a composition comprising (S) 2-amino-1-(4-chloro-phenyl)-1-[4-( | 11-03-2011 |
| 20110269807 | NOVEL TREATMENT FOR AGE RELATED MACULAR DEGENERATION AND OCULAR ISCHEMIC DISEASE ASSOCIATED WITH COMPLEMENT ACTIVATION BY TARGETING 5-LIPOXYGENASE - The invention relates to compounds, compositions, drug delivery systems, and methods for treating age-related macular degeneration (AMD) and ocular ischemic disease in an individual in need. | 11-03-2011 |
| 20090163569 | PROCESS FOR THE PRODUCTION OF AMIDES - The present invention relates to a process for the preparation of compounds of formula (I) wherein R | 06-25-2009 |
| 20090149524 | N-(Phenylmethyl)-2-(1H-Pyrazol-4-yl) Acetamide Derivatives as P2X7 Antagonists for the Treatment of Pain, Inflammation and Neurodegeneration - The present invention relates to novel pyrazole derivatives of formula (I) which bind to the P2X7 receptor and are capable of interfering with the effects of ATP at the P2X7 receptor: | 06-11-2009 |
| 20090069398 | Pyrazolyl Carboxamides - Novel pyrazolylcarboxamides of the formula (I) | 03-12-2009 |
| 20090118346 | Alkyl-Analide Producing Method - New pyrazolylcarboxanilides of the formula (I) | 05-07-2009 |
| 20090054509 | Octahydropentalene-Substituted Pyrazoline Derivatives, Their Prepartion and Use as Medicaments - The present invention relates to octahydropentalene-substituted pyrazoline compounds of formula I, methods for their preparation, medicaments comprising these compounds as well as their use for the preparation of a medicament for the treatment of humans and animals. (1) | 02-26-2009 |
| 20100004306 | PIGF-1 Assay and kits and components thereof - The present disclosure relates to, among other things, methods for determining whether a subject receiving treatment with a drug has obtained an efficacious blood level of the drug. Moreover, the present disclosure also relates to methods of determining whether a subject predisposed to or suffering from a disease will benefit from treatment with a drug, and the response of a subject receiving treatment (e.g., such as for cancer) by monitoring biomarkers of angiogenesis. In particular, the disclosure relates to PlGF-1 companion diagnostic methods and products. | 01-07-2010 |
| 20090054508 | IGF-1R INHIBITOR - The present invention provides a type I insulin-like growth factor receptor (IGF-1R) inhibitor comprising, as an active ingredient, an indazole derivative represented by Formula (I): | 02-26-2009 |
| 20110230537 | NOVEL PYRAZOLE-4-N-ALKOXYCARBOXAMIDES AS MICROBIOCIDES - Compounds of formula (I) in which the substituents are as defined in claim | 09-22-2011 |
| 20110230536 | PHENYLPYRAZOLE INHIBITORS OF STORE OPERATED CALCIUM RELEASE - Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of store-operated calcium (SOC) channels. Also described herein are methods of using such SOC channel modulators, alone and in combination with other compounds, for treating diseases, disorders or conditions that would benefit from inhibition of SOC channel activity. | 09-22-2011 |
| 20080287517 | Pyrazole Derivatives as Cb1 Modulators - The present invention relates to compounds of formula I | 11-20-2008 |
| 20090239923 | CONCENTRATED AQUEOUS AND/OR ETHANOLIC SOLUTION OF 4-METHYLPYRAZOLE (FOMEPIZOLE) - A composition of matter comprising fomepizole and water wherein the content of water is about 3% to about 40% by weight, and methods of making fomepizole solutions effective to reduce the freezing point of pure fomepizole to less than about 18° C. | 09-24-2009 |
| 20090221661 | PHOSPHODIESTERASE 4 INHIBITORS - Selective PDE4 inhibition is achieved by aryl and heteroaryl pyrazole compounds. The compounds exhibit improved PDE4 inhibition as compared to compounds such as rolipram and show selectivity with regard to inhibition of other classes of PDEs. | 09-03-2009 |
| 20090253766 | THIOPHENE DERIVATIVES AS FACTOR XIA INHIBITORS - The present invention provides compounds of Formula (I): | 10-08-2009 |
| 20100197753 | Benzamides Useful as S1P Receptor Modulators - The invention relates to novel aromatic compounds of the formula | 08-05-2010 |
| 20110060022 | 4-[4-(2-adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]Benzoic Acid - 465 - 4-[4-(2-Adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]benzoic acid and pharmaceutically-acceptable salts thereof and a particular crystalline form of the Agent (Form 1); their use in the inhibition of 11βHSD1, processes for making them and pharmaceutical compositions comprising them are also described. | 03-10-2011 |
| 20100152265 | INDAZOLE DERIVATIVES - Compounds represented by the Formula (A-1) and the Formula (1) or salt thereof are provided. The compounds represented by the Formula (A-1) and the Formula (1) or salt thereof have a β3 adrenergic receptor agonist activity, and therefore are useful as an agent for the prevention and treatment of diabetes, obesity, hyperlipidemia, depression, biliary stone, a disorder derived from hyperactivity of biliary tract, a disorder derived from hyperactivity of digestive tract, interstitial cystitis, overactive bladder, urinary incontinence or a disorder derived from decreased tear secretion, etc. | 06-17-2010 |
| 20100222404 | INDAZOLE DERIVATIVE DIHYDROCHLORIDE - There are provided (R)—N-[3-[2-[2-(3-methylindazol-6-yloxy)ethylamino]-1-hydroxyethyl]phenyl]methanesulfonamide dihydrochloride and a crystal thereof, and a crystal of the dihydrochloride salt having one or more major peaks at 2θ selected from the group consisting of approximately 12.8°, 21.8° and 25.0° in the powder X-ray diffraction spectrum. | 09-02-2010 |
| 20100216859 | CURCUMIN ANALOG COMPOSITIONS AND RELATED METHODS - Novel curcumin-analog compounds are disclosed that are antioxidants useful in inhibition of pro-inflammation, angiogenic, and vascular permeability factors and elimination of reactive oxygen species. The curcumin compounds specifically inhibit VEGF and are useful in treating various diseases that are mediated through the oxidative stress pathway, including those that are characterized by inflammation, angiogenesis, or vascular leakage. | 08-26-2010 |
| 20100144818 | 1-BENZYLPYRAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF - The present invention relates to compounds corresponding to formula (I): | 06-10-2010 |
| 20100144817 | FUNGICIDEL N-CYCLOALKYL-BENZYL-THIOCARBOXAMIDES OR N-CYCLOALKYL-BENZYL-N'-SUBSTITUTED-AMIDINE DERIVATIVES - The present invention relates to N-cycloalkyl-benzyl-thiocarboxamide or N-cycloalkyl-benzyl-N-substituted-carboximidamide amide derivatives of formula (I) wherein A represents a carbo-linked, unsaturated or partially saturated, 5-membered heterocyclyl; T represents S, N—R | 06-10-2010 |
| 20090076113 | Biphenylcarboxamides for controlling micro-organisms - Novel biphenylcarboxamides of the formula (I) | 03-19-2009 |
| 20100152266 | Iodopyrazolyl Carboxanilides - This invention relates to novel intermediates used in the preparation of iodopyrazolylcarboxanilides of the formula (I) | 06-17-2010 |
| 20100120883 | NOVEL COMPOUNDS - The present invention provides compounds of formula (I): | 05-13-2010 |
| 20110028530 | NOVEL CRYSTALLINE FORMS OF 4-[4-(2-ADAMANTYLCARBAMOYL)-5-TERT-BUTYL-PYRAZOL-1-YL]BENZOIC ACID 471 - New crystalline forms of 4-[4-(2-adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]benzoic acid; their use in the inhibition of 11βHSD1, processes for making them and pharmaceutical compositions comprising them are also described. | 02-03-2011 |
| 20110028529 | NOVEL CRYSTALLINE FORMS OF 4-[4-(2-ADAMANTYLCARBAMOYL)-5-TERT-BUTYL-PYRAZOL-1-YL]BENZOIC ACID 471 - New crystalline forms of 4-[4-(2-adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]benzoic acid; their use in the inhibition of 11βHSD1, processes for making them and pharmaceutical compositions comprising them are also described. | 02-03-2011 |
| 20120142748 | NOVEL CANNABINOID RECEPTOR LIGANDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND PROCESS FOR THEIR PREPARATION - The present invention relates to novel cannabinoid receptor modulators, in particular cannabinoid 1 (CB1) or cannabinoid 2 (CB2) receptor modulators, and uses thereof for treating diseases, conditions and/or disorders modulated by a cannabinoid receptor. | 06-07-2012 |
| 20100317708 | CARCINOMA DIAGNOSIS AND TREATMENT, BASED ON ODC1 GENOTYPE - The present invention provides methods and kits a) for predicting colorectal cancer patient survival, as well as the survival of patients harboring other invasive cancers where cellular proliferation and carcinogenesis is linked, in part, to high levels of ODC activity and increased cellular polyamine contents, and b) for selecting the corresponding treatment options for such patients based on the allelic nucleotide sequence or SNP at position +316 of the ODC1 promoter gene as well as cancer treatment methods, in each case, which include the determination of the ODC1 promoter +316 position genotype, as a means to guide treatment selection. | 12-16-2010 |
| 20110021593 | NOVEL CRYSTAL OF SUBSTITUTED PHENYLALKANOIC ACID ESTER AND PROCESS FOR PRODUCING THE SAME - [Object] In the case of using 3-[3-amino-4-(indan-2-yloxy)-5-(1-methyl-1H-indazol-5-yl)phenyl]propionic acid, methyl 3-[4-(indan-2-yloxy)-3-(1-methyl-1H-indazol-5-yl)-5-nitrophenyl]propionate, or methyl 3-[3-amino-4-(indan-2-yloxy)-5-(1-methyl-1H-indazol-5-yl)phenyl]propionate as a medicine, more preferable aspects or improved methods are provided. | 01-27-2011 |
| 20110178148 | SUBSTITUTED 5-VINYLPHENYL-1-PHENYL-PYRAZOLE CANNABINOID MODULATORS - This invention is directed to a cannabinoid modulator compound of formula (I): | 07-21-2011 |
| 20110034529 | BENZENE, PYRIDINE, AND PYRIDAZINE DERIVATIVES - Disclosed are compounds and pharmaceutically acceptable salts of Formula I | 02-10-2011 |
| 20090143455 | Pyrazoles Useful in the Treatment of Inflammation - There is provided compounds of formula I, | 06-04-2009 |
| 20100056595 | Pyrazole Derivatives as P2X7 Modulators - The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof: | 03-04-2010 |
| 20100069456 | USE OF AN INDAZOLEMETHOXYALKANOIC ACID FOR REDUCING TRIGLYCERIDE, CHOLESTEROL AND GLUCOSE LEVELS - Use of a compound of formula (I) in which R, R′ and R″ have the meanings given in the description, optionally in the form of a salt thereof with a pharmaceutically acceptable organic or mineral base, to prepare a pharmaceutical composition for reducing the blood triglyceride, cholesterol and glucose levels. | 03-18-2010 |
| 20090215850 | METHOD FOR TREATING CB2 RECEPTOR MEDIATED PAIN - The present invention is directed to a method for treating, ameliorating or preventing CB2 receptor mediated pain in a subject in need thereof comprising administering to the subject an effective amount of a compound of formula (I): | 08-27-2009 |
| 20100063125 | MELATONIN DERIVATIVES AND THEIR USE AS ANTIOXIDANTS - The present subject matter relates generally to antioxidant compounds having the formula (I): wherein each of R | 03-11-2010 |
| 20100069455 | BONE MODEL, BONE FILLER AND PROCESS FOR PRODUCING BONE FILLER - A method for producing a bone filler basically comprising: a bone model producing step (step 1) for producing a bone model; a figure forming material filling step (step 2) for filling a figure forming material into a bone defect site of the bone model obtained in the bone model producing step; and a bone filler producing step (step 3) for producing a bone filler which is to be filled in a bone defect site based on the figure forming material filled in the bone defect site of the bone model in the figure forming material filling step. | 03-18-2010 |
| 20120202867 | NOVEL MICROBIOCIDES - Compounds of formula (I), in which the substituents are as defined in claim | 08-09-2012 |
| 20090137655 | Non-Steroidal Ligands for the Glucocorticoid Receptor, Compositions and Uses Thereof - The invention provides non-steroidal ligands for the glucocorticoid receptor, methods for making non-steroidal ligands of the glucocorticoid receptor, compositions of non-steroidal ligands of the glucocorticoid receptor and methods of using non-steroidal ligands and compositions of non-steroidal ligands of the glucocorticoid receptor for treating or preventing diseases (e.g., obesity, diabetes, depression, neurodegeneration or an inflammatory disease) associated with glucocorticoid binding to the glucocorticoid receptor. | 05-28-2009 |
| 20100286222 | USE OF INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE TO SYNERGIZE ACTIVITY OF COX AND 5-LOX INHIBITORS - The invention relates to methods, compositions, and uses of those compositions for making medicaments, for potentiating the beneficial effects of inhibitors of COX-1, COX-2, and 5-LOX, and reducing adverse effects, by also administering inhibitors of soluble epoxide hydrolase (“sEH”), with or without also administering one or more cis-epoxyeicosantrienoic acids. The invention further relates to the use of inhibitors of sEH as analgesics and to methods and compositions of epoxides of eicosapentaenoic acid and docosahexaenoic acid, optionally with an inhibitor of sEH, to reduce pain or inflammation or both. | 11-11-2010 |
| 20100286221 | Fungicide N-Cycloalkyl-Benzyl-Amide Derivatives - The present invention relates to N-cycloalkyl-benzyl-amide derivatives of formula (I) wherein the substituents are as in the description, their process of preparation, their use as fungicide active agents, particularly in the form of fungicide compositions, and methods for the control of phytopathogenic fungi, notably of plants, using these compounds or compositions: | 11-11-2010 |
| 20110053999 | 4-METHYLPYRAZOLE FORMULATIONS FOR INHIBITING ETHANOL INTOLERANCE - Provided herein are methods, compositions and formulations to prevent or ameliorate ethanol intolerance, reduce or ameliorate symptoms associated with acetaldehyde accumulation accompanying ethanol consumption, or reduce the risk of diseases or disorders caused by acetaldehyde accumulation, comprising administering 4-MP, or physiologically acceptable salts thereof, to subjects with reduced or absent aldehyde dehydrogenase subtype 2 (ALDH2) activity. | 03-03-2011 |
| 20120302617 | Phenyl and Benzodioxinyl Substituted Indazoles Derivatives - A compound of formula Ia: | 11-29-2012 |
| 20100305181 | METHODS FOR TREATING A VARIETY OF DISEASES AND CONDITIONS, AND COMPOUNDS USEFUL THEREFOR - In accordance with the present invention, there are provided novel compounds that have a variety of properties, i.e., antioxidant, anti-inflammatory, antiviral, antibacterial, and antifungal properties. Invention compounds, therefore, have the ability to impart a variety of beneficial physiological effects, e.g., to protect neurons and/or to promote neuroregeneration and/or to promote memory formation and/or to act as protein phosphatase or kinase inhibitors and/or to act as lipoxygenase inhibitors. Such compounds are useful for treatment of a variety of indications, including neurodegenerative diseases and conditions, diabetes, ischemia associated with heart disease, and memory deficit. In another aspect of the present invention, there are also provided formulations containing one or more of the above-described compounds, optionally further containing additional neurologically active compound(s) and/or adjuvants to facilitate delivery thereof across the blood/brain barrier. In still another aspect of the present invention, there are further provided methods for treating a wide variety of neurological indications, e.g., acute neural injuries, chronic injuries, promoting memory formation, and the like. | 12-02-2010 |
| 20090209607 | INHIBITORS OF AKT ACTIVITY - Invented are novel heterocyclic carboxamide compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis. | 08-20-2009 |
| 20120071535 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF - Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors. | 03-22-2012 |
| 20090176854 | PYRAZOLE DERIVATIVES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE - Pyrazoles having a naphthyl group attached are disclosed. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included. | 07-09-2009 |
| 20110190365 | Insecticidal 4-phenyl-1H-pyrazoles - The present invention relates to novel 4-phenyl-1H-pyrazoles and their use as insecticides and/or parasiticides and also to processes for their preparation and to compositions comprising such phenylpyrazoles. | 08-04-2011 |
| 20100022611 | 1,5-Diaryl-Pyrazoles As Cannabinoid Receptor Neutral Antagonists Useful As Therapeutic Agents - The present invention pertains to cannabinoid (CB) receptor neutral antagonists, and especially CB1 neutral antagonists, and including, for example, certain | 01-28-2010 |
| 20110218225 | NON-STEROIDAL LIGANDS FOR THE GLUCOCORTICOID RECEPTOR, COMPOSITIONS AND USES THEREOF - The invention provides non-steroidal ligands for the glucocorticoid receptor, methods for making non-steroidal ligands of the glucocorticoid receptor, compositions of non-steroidal ligands of the glucocorticoid receptor and methods of using non-steroidal ligands and compositions of non-steroidal ligands of the glucocorticoid receptor for treating or preventing diseases (e.g., obesity, diabetes, depression, neurodegeneration or an inflammatory disease) associated with glucocorticoid binding to the glucocorticoid receptor. | 09-08-2011 |
| 20100016397 | Pyrrole and Pyrazole DAAO Inhibitors - Methods for increasing D-Serine concentration and reducing concentration of the toxic products of D-Serine oxidation, for enhancing learning, memory and/or cognition, or for treating schizophrenia, Alzheimer's disease, ataxia or neuropathic pain, or preventing loss in neuronal function characteristic of neurodegenerative diseases involve administering to a subject in need of treatment a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt or solvate thereof: | 01-21-2010 |
| 20100016396 | PYRAZOLE COMPOUND - The present invention aims to provide an agent for the prophylaxis or treatment of diabetes, which has a superior hypoglycemic action, and is associated with a fewer side effects such as body weight gain and the like. | 01-21-2010 |
| 20080207724 | Use of Inhibitors of Histone Deacteylases in Combination With Compounds Acting as Nsaid for the Therapy of Human Diseases - The present invention relates to the medical use of compounds acting as inhibitors of enzymes having histone deacetylase activity in conditions where their combination with compounds known as NSAID's, Non Steroidal Anti Inflammatory Drugs, causes an enhanced beneficial therapeutic effect. These conditions comprise cancer, cancer predisposing conditions, inflammatory and metabolic diseases. Furthermore, the invention includes the manufacture of clinically used medicaments for the therapy of the diseases mentioned herein, administering the compounds separately in the form of two individual drugs or in an administrative form which contains both drugs in a single application unit. | 08-28-2008 |
| 20090036511 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING METABOLIC DISORDERS, INCLUDING OBESITY AND DIABETES - The present invention provides novel pyrazoles that are useful as cannabinoid receptor antagonists and pharmaceutical compositions thereof and methods of using the same for treating obesity, diabetes, and/or cardiometabolic disorders. | 02-05-2009 |
| 20090197935 | PRIMARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO - The present invention pertains to certain compounds of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the 5-HT | 08-06-2009 |
| 20100056594 | PLANT DISEASE AND INSECT DAMAGE CONTROL COMPOSITION, AND PLANT DISEASE AND INSECT DAMAGE PREVENTION METHOD - A composition including active ingredients of penthiopyrad and at least one neonicotinoid compound chosen from the group consisting of dinotefuran, clothianidin, nitenpyram, thiamethoxam, imidacloprid, thiacloprid, and acetamiprid, and a plant disease and insect damage prevention method of applying such a composition to a plant seed, are provided. According to the invention, a composition and a prevention method are provided which demonstrate a high degree of prevention effect and residual effectiveness against plural types of disease and insect damage, and also demonstrate a stable preventing effect to currently emerging resistant pathogens and resistant pest insects. | 03-04-2010 |
| 20120065239 | PROCESS FOR THE PRODUCTION OF AMIDES - The present invention relates to a process for the preparation of compounds of formula I | 03-15-2012 |
| 20110092558 | NOVEL MICROBIOCIDES - Compounds of formula (I) in which the substituents are as defined in claim | 04-21-2011 |
| 20100197754 | CRYSTALLINE N--5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride - An improved AKT inhibiting compound, crystalline N-{(1S)-2-amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride. | 08-05-2010 |
| 20110105579 | Plant Health Composition - The present invention relates to a method for improving the plant health of at least one plant variety, which method comprises treating the plant propagules with an amide compound having the formula I (compound I). The present invention also N relates to a method for improving the plant health of at least one plant variety, which method comprises treating the plant propagules with a mixture comprising an amide compound having the formula I (compound I) and at least one compound selected from the group consisting of a further fungicide Il (compound II), a further fungicide III (compound lib) and an insecticide III (compound III). | 05-05-2011 |
| 20100093820 | CRYSTALLINE PYRAZOLES - The present invention relates to crystal forms of 4-[5-(4-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-benzenesulfonamide and methods for preparation, interconversion, and isolation of such crystals. | 04-15-2010 |
| 20100093819 | PHENYLPROPIONIC ACID DERIVATIVE AND USE THEREOF - A compound represented by the following general formula (1) or a salt thereof, which has superior inhibitory activity against type 4 PLA | 04-15-2010 |
| 20120122946 | POLYMORPHISMS FOR PREDICTING DISEASE AND TREATMENT OUTCOME - The invention provides compositions and methods for determining the increased risk for recurrence of certain cancers and the likelihood of successful treatment with one or both of chemotherapy and radiation therapy. The methods comprising determining the type of genomic polymorphism present in a predetermined region of the gene of interest isolated from the subject or patient. Also provided are nucleic acid probes and kits for determining a patient's cancer risk and treatment response. | 05-17-2012 |
| 20090131497 | INDOLINE-SUBSTITUTED PYRAZOLINE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS - The present invention relates to indoline-substituted pyrazoline compounds of formula (I), methods for their preparation, medicaments comprising these compounds as well as their use for the preparation of a medicament for the treatment of humans and animals. | 05-21-2009 |
| 20110184038 | METHODS AND COMPOSITIONS OF SMALL MOLECULE MODULATORS OF HEPATOCYTE GROWTH FACTOR (SCATTER FACTOR) ACTIVITY - The present invention provides compositions and formulations of compounds having formula (I) and pharmaceutically acceptable derivatives thereof, wherein p, R | 07-28-2011 |
| 20120165384 | INHIBITION OF HISTONE ACETYLTRANSFERASES BY CTK7A AND METHODS THEREOF - The present disclosure relates to a method for inhibiting histone acetyltransferases by derivative of curcumin, particularly CTK7A. The present disclosure also relates to identification of induction of autoacetylation of p300 and its inhibition by CTK7A. The disclosure also relates to induction of NPM1 and GAPDH overexpression and corresponding hyperacetylation of histone and methods thereof. | 06-28-2012 |
| 20080207723 | Methods for Detecting and Monitoring COX-2 RNA in Plasma and Serum - This invention provides methods for detecting or inferring the presence of malignant or premalignant cells in a human wherein the malignant or premalignant cells express COX-2. The methods of the invention detect extracellular COX-2 RNA in blood, plasma, serum, and other bodily fluids. The inventive methods are useful for aiding detection, diagnosis, monitoring, treatment, or evaluation of neoplastic disease, and for identifying individuals for whom COX-2 directed therapies would be beneficial. | 08-28-2008 |
| 20100173966 | PYRAZOLE CARBOXYLIC ACID AMIDES USEFUL AS MICROBIOCIDES - Compounds of the formula (I), in which the substituents are as defined in claim | 07-08-2010 |
| 20100048660 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY - There are disclosed compound of Formula (I) or (II) wherein A | 02-25-2010 |
| 20100273851 | METHODS OF USING PROTEINACIOUS CHANNELS TO IDENTIFY PHARMACEUTICAL TREATMENTS AND RISKS, AND TREATMENTS RESULTING THEREFROM - Methods and therapeutic strategies utilizing proteinacious channels in lipid membranes of mammalian cells. The methods entail administering a pharmaceutical to a lipid membrane of a mammalian cell, and then determining the effect of the pharmaceutical on the electrophysiology of at least one proteinacious channel of the lipid membrane, wherein the proteinacious channel is a Kv7 potassium channel and/or a L-type calcium channel of an airway smooth muscle cell (ASMC). The method can be used to identify pharmaceuticals that may be used to treat asthmatic and other bronchospastic conditions that can lead to airway obstruction, or to perform drug screening to assess potential risk of pharmaceuticals. | 10-28-2010 |
| 20120252857 | GENOTYPE SPECIFIC METHODS FOR TREATING HUMAN SUBJECTS USING 4-METHYLPYRAZOLE - Provided herein are methods of administering 4-methylpyrazole (4-MP), or physiologically acceptable salts thereof, to subjects of genetic subpopulations expressing specific polymorphisms of the alcohol dehydrogenase and aldehyde dehydrogenase genes. Also provided herein are methods to prevent or ameliorate ethanol intolerance, reduce or ameliorate symptoms associated with acetaldehyde accumulation accompanying ethanol consumption, or reduce the risk of diseases or disorders caused by consumption of ethanol, comprising administering 4-MP, or physiologically acceptable salts thereof, to subjects of these subpopulations. | 10-04-2012 |
| 20090036510 | 1, 2-DIARYL PYRAZOLES USEFUL AS ANALGETIC AND ANTIINFLAMMATORY AGENTS - The present invention relates to new compounds of formula (I), (I) wherein the meaning of R | 02-05-2009 |
| 20120264798 | PRODRUGS OF INHIBITORS OF PLASMA KALLIKREIN - This invention provides new pharmaceutically useful compounds that are prodrugs of inhibitors of plasma kallikrein and methods and compositions for preventing or treating plasma kallikrein dependent diseases or conditions, such as diabetic macular edema or hemorrhagic stroke, by administering prodrugs of the formula: | 10-18-2012 |
| 20120264800 | KINASE INHIBITORS AND METHOD OF TREATING CANCER - The invention is directed to a compound represented by the following structural formula and pharmaceutically acceptable salts thereof: | 10-18-2012 |
| 20120264799 | INDANE-AMINE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS - The present invention relates to indane-amine derivatives, to processes for the preparation thereof, to medicaments comprising them as well as to their use for the preparation of a medicament for the treatment of 5HT7 receptor mediated diseases or conditions. | 10-18-2012 |
| 20110003874 | NOVEL 1-BENZYL-3-HYDROXYMETHYLINDAZOLE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF MCP-1, CX3CR1 AND P40 - The present invention relates to novel 1-benzyl-3-hydroxymethylindazole derivatives according to Formula (I) described in the claims, and to a pharmaceutical composition comprising them, together with a pharmaceutically acceptable vehicle. In addition, the present invention relates to the use of 1-benzyl-3-hydroxymethylindazole derivatives for the preparation of a pharmaceutical composition that is active in the treatment of diseases based on the expression of MCP-1, CX3CR1 and p40, and to their use in a method for treating or preventing diseases based on the expression of MCP-1, CX3CR1 and p40. | 01-06-2011 |
| 20120322841 | Aldosterone Synthase Inhibitor - The present invention provides aldosterone synthase inhibitors of the formula: | 12-20-2012 |
| 20120322843 | GENOTYPE SPECIFIC METHODS FOR TREATING HUMAN SUBJECTS USING 4-METHYLPYRAZOLE - Provided herein are methods of administering 4-methylpyrazole (4-MP), or physiologically acceptable salts thereof, to subjects of genetic subpopulations expressing specific polymorphisms of the alcohol dehydrogenase and aldehyde dehydrogenase genes. Also provided herein are methods to prevent or ameliorate ethanol intolerance, reduce or ameliorate symptoms associated with acetaldehyde accumulation accompanying ethanol consumption, or reduce the risk of diseases or disorders caused by consumption of ethanol, comprising administering 4-MP, or physiologically acceptable salts thereof, to subjects of these subpopulations. | 12-20-2012 |
| 20120322842 | HETEROCYCYL-SUBSTITUTED-ALKYLAMINOPHENYL DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS - The present invention relates to heterocyclyl-substituted alkylamino phenyl derivatives (I) to processes for the preparation thereof, to medicaments comprising them as well as to their use for the preparation of a medicament for the treatment of 5HT7 receptor mediated diseases or conditions. In the compounds (I) x-y-z together form —N—N═CR | 12-20-2012 |
| 20110237640 | PYRAZOLE PHENYL DERIVATIVES - The invention relates to compounds of the formula I: | 09-29-2011 |
| 20100234440 | NOVEL CRYSTAL OF SUBSTITUTED PHENYLALKANOIC ACID ESTER AND PROCESS FOR PRODUCING THE SAME - [Object] In the case of using 3-[3-amino-4-(indan-2-yloxy)-5-(1-methyl-1H-indazol-5-yl)phenyl]propionic acid, methyl 3-[4-(indan-2-yloxy)-3-(1-methyl-1H-indazol-5-yl)-5-nitrophenyl]propionate, or methyl 3-[3-amino-4-(indan-2-yloxy)-5-(1-methyl-1H-indazol-5-yl)phenyl]propionate as a medicine, more preferable aspects or improved methods are provided. | 09-16-2010 |
| 20100234439 | THERAPEUTIC AGENTS - The present invention relates to a 1,5-diphenylpyrazole compound and its use in the treatment of obesity, psychiatric and neurological disorders, to methods for the its therapeutic use and to pharmaceutical compositions containing them. | 09-16-2010 |
| 20100234438 | THERAPEUTIC AGENTS - The present invention relates to a 1,5-diphenylpyrazole compound and its use in the treatment of obesity, psychiatric and neurological disorders, to methods for the its therapeutic use and to pharmaceutical compositions containing them. | 09-16-2010 |
| 20120329847 | PYRAZOLE MICROBIOCIDES - Compounds of formula (I) wherein R | 12-27-2012 |
| 20120283307 | USE OF AN INDAZOLEMETHOXYALKANOIC ACID FOR REDUCING TRIGLYCERIDE, CHOLESTEROL AND GLUCOSE LEVELS - A method of treating insulin resistance, obesity and metabolic syndrome by administering an indazolemethoxyalkanoic acid as described herein. | 11-08-2012 |
| 20120283306 | MOUSE MODEL FOR AVM - Arteriovenous malformation, or Arteriovenous vascular malformation (AVM) is a congenic disorder characterized by an abnormal connection between veins and arteries, resulting in hemorrhaging and even death. A lack of good animal models has long been an obstacle for identifying effective drugs for neurological AVM treatment. Describe herein is a mouse model for AVM that includes a viable, postnatal animal with a conditional deletion of the activin receptor-like kinase 1 (Alk1;Acvrl1). The Alk1-cKO mouse model can be used to identify genes and gene products that are upregulated in subjects suffering from AVM. For example, it has been discovered Agpt2, IL1β, and TNF-α, are upregulated in Alk1-cKO compared to controls. Pharmaceutical compositions for treatment of AVM are disclosed. Preferred compositions inhibit or decrease expression of angiogenic and pro-inflammatory factors, such as VEFG, Cox-2, Agpt2, IL1β, TNF-α, and matrix metalloproteinases. Methods of determining efficacy of potential AVM therapeutics are also disclosed. | 11-08-2012 |
| 20120289570 | COMPOSITIONS AND METHODS FOR TREATING AND/OR PREVENTING CANCER BY INHIBITING FATTY ACID BINDING PROTEINS - The present invention concerns methods and compositions for the inhibition or reduction of the primary tumor and metastasis by inhibition of fatty acid binding proteins. | 11-15-2012 |
| 20100179206 | CONTROL OF ECTOPARASITES - Disclosed is a method of controlling ectoparasites that infest companion and livestock animals by applying to the animal an effective amount of 4-tert-butylphenethyl quinazolin-4-yl ether or 4-chloro-5-ethyl-2-methyl-N-[(4-tert-butylphenyl)methyl]pyrazole-3-carboxamide or 5-chloro-N-[2-[4-(2-ethoxyethyl)-2,3-dimethylphenoxy]ethyl]-6-ethyl-4-pyrimidinamine or 4-chloro-3-ethyl-1-methyl-N-[4-(p-tolyloxy)benzyl]pyrazole-5-carboxamide | 07-15-2010 |
| 20130012561 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF - Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors. | 01-10-2013 |
| 20120149750 | ARYLOAZOL-2-YL CYANOETHYLAMINO COMPOUNDS, METHOD OF MAKING AND METHOD OF USING THEREOF - The present invention relates to novel aryloazol-2-yl-cyanoethylamino derivatives of formula (I): | 06-14-2012 |
| 20130023576 | Pyrazole Compounds as CRTH2 Antagonists - Pyrazole compounds of formula (Ia) or (Ib) and pharmaceutically acceptable salts thereof, | 01-24-2013 |
| 20080234349 | PPAR active compounds - Compounds are described that are active on at least one of PPARα, PPARδ, and PPARγ, which are useful for therapeutic and/or prophylactic methods involving modulation of at least one of PPARα, PPARδ, and PPARγ. | 09-25-2008 |
| 20120252858 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF BETA-AMYLOID DISEASES AND SYNUCLEINOPATHIES - Dihydroxyaryl compounds and pharmaceutically acceptable esters, their synthesis, pharmaceutical compositions containing them, and their use in the treatment of β-amyloid diseases, such as observed in Alzheimer's disease, and synucleinopathies, such as observed in Parkinson's disease, and the manufacture of medicaments for such treatment. | 10-04-2012 |
| 20130096174 | PLANT DISEASE CONTROL COMPOSITION AND METHOD OF CONTROLLING PLANT DISEASE - A plant disease control composition comprising a carboxamide compound represented by formula (I) whose enantiomer ratio R form/S form of the carboxamide compound is 80/20 or more has an excellent plant disease controlling activity. | 04-18-2013 |
| 20130102648 | PESTICIDAL COMPOSITION AND ITS USE - A composition comprising a carboxamide compound represented by following formula (I), wherein R | 04-25-2013 |
| 20130102647 | PLANT DISEASE CONTROL COMPOSITION AND ITS USE - A plant disease control composition comprising a carboxamide compound represented by following formula (I), wherein R | 04-25-2013 |
| 20130123323 | FUNGICIDAL PYRAZOLES - Disclosed are compounds of Formula 1, including all geometric and stereoisomers, N-oxides, and salts thereof, | 05-16-2013 |
| 20130123322 | BENZOCYCLOALKENES AS ANTIFUNGAL AGENTS - The present invention relates to fungicidal benzocycloalkene carboxamides or their thiocarboxamide derivatives of formula (I), their process of preparation and intermediate compounds for their preparation, their use as fungicides, particularly in the form of fungicidal compositions and methods for the control of phytopathogenic fungi of plants using these compounds or their compositions. | 05-16-2013 |
| 20130131135 | COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE - The present invention provides a compound, that is a 1-[(2-{[(alkyl or aryl)methyl]oxy}halo or haloalkyl substituted-phenyl)alkyl]-5-hydrocarbyl or substituted hydrocarbyl-1H-pyrazole carboxylic acid or alkylenylcarboxylic acid or a hydrocarbyl or substituted hydrocarbyl sulfonamide of said carboxylic acid or said alkylenylcarboxylic acid, provided however said compound is not a 3-carboxylic acid, a sulfonamide thereof, or a 3-methylenylcarboxylic acid. The compound may be represented by the following formula | 05-23-2013 |
| 20130131134 | PHENYLPROPIONIC ACID DERIVATIVE AND USE THEREOF - A compound represented by the following general formula (1) or a salt thereof, which has superior inhibitory activity against type 4 PLA | 05-23-2013 |
| 20130123321 | PLANT DISEASE CONTROL COMPOSITION AND ITS USE | 05-16-2013 |
| 20080200530 | Diaryl and Arylheteroaryl Urea Derivatives as Modulators of 5-Ht2a Serotonin Receptor Useful for the Prophylaxis or Treatment of Progressive Multifocal Leukoencephalopathy - The present invention relates to certain pyrazole derivatives of Formula (I) and pharmaceutical compositions thereof that modulate the activity of the 5-HT2A serotonin receptor. Compounds and pharmaceutical compositions thereof are directed to methods useful in the prophylaxis or treatment of progressive multifocal leukoencephalopathy. | 08-21-2008 |
| 20130150419 | 4-METHYLPYRAZOLE FORMULATIONS FOR INHIBITING ETHANOL INTOLERANCE - Provided herein are methods, compositions and formulations to prevent or ameliorate ethanol intolerance, reduce or ameliorate symptoms associated with acetaldehyde accumulation accompanying ethanol consumption, or reduce the risk of diseases or disorders caused by acetaldehyde accumulation, comprising administering 4-MP, or physiologically acceptable salts thereof, to subjects with reduced or absent aldehyde dehydrogenase subtype 2 (ALDH2) activity. | 06-13-2013 |
